Clinical trial NCT04016389: FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
Official title: FIGO 2018 Stage IB2 (> 2 to ≤4cm) Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cervical Cancer
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: Hotel Dieu Hospital
name: The Netherlands Cancer Institute
First posted: 2019-07-11
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment.

Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer.

The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy drug cisplatin or carboplatin, with a chemotherapy drug called paclitaxel. These are common chemotherapy drugs used in the treatment of women with cervical cancers.

Detailed description: All participants will first receive neo-adjuvant platinum-based chemotherapy. Once the neo-adjuvant chemotherapy has been completed, participants will be assessed by imaging scans to see whether they have a response to the treatment.

If participants are responding to treatment, they will then have a trachelectomy. After surgery, participants will be assessed and the study doctor will determine whether adjuvant treatment is needed. Adjuvant treatment may include chemotherapy and radiotherapy, or have a hysterectomy done.

If participants do not respond to or their disease worsens after neo-adjuvant treatment, participants will receive adjuvant treatment with chemotherapy and radiotherapy or have a hysterectomy done.

Eligibility criteria: Inclusion Criteria:

Part 1 - Eligibility Criteria for Neoadjuvant Chemotherapy

* Patients must have histologically confirmed invasive cervical cancer with adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring \>2 cm - ≤4 cm by radiological imaging (MRI).
* Patients must be premenopausal and wish to preserve fertility.
* At time of registration, patient may not have had any prior therapy to treat their cancer lesion.
* Eastern Cooperative Group (ECOG) performance status ≤ 2.
* Within 7 days of the proposed start of treatment, patients must have normal organ and marrow function.
* No evidence of active uncontrolled infection (patients on antibiotics are eligible).
* Patient must have disease that is measurable per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
* Ability to understand and willing to sign a written informed consent document.
* Patients must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least one year after the fertility-sparing surgery (FSS) procedure. A serum pregnancy test within 72 hours prior to study registration is required.

Part 2 - Eligibility Criteria for Fertility Sparing Surgery (FSS)

* Completed 3 cycles of neo-adjuvant chemotherapy and achieved a complete response (CR) or partial response (PR) with reduction of the lesion to \<2 cm on physical examination and MRI.

Exclusion Criteria:

Part 1 - Exclusion Criteria for Neoadjuvant Chemotherapy

* Patients who have had chemotherapy or radiotherapy or surgery for their cancer.
* Patients who are receiving any other investigational agents.
* Patients with other cancers requiring ongoing treatment.
* Patients with known / evidence of brain metastases are excluded from participation in this clinical trial.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, carboplatin, or cisplatin or other agents used in study.
* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Patients who are pregnant or breastfeeding
* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues.

Part 2 - Exclusion Criteria for Fertility Sparing Surgery

* Patient unable to complete 3 cycles of neoadjuvant chemotherapy
* Suboptimal response to neoadjuvant chemotherapy according to investigator
* Residual lesion \> 2cm or disease progression while on chemotherapy

Primary outcomes:
measure: Rate of functional uterus defined as successful fertility sparing surgery (FSS) with no adjuvant therapy
timeFrame: 2 years
Secondary outcomes:
measure: Number of side effects
timeFrame: 2 years
measure: Rate of completion of neo-adjuvant chemotherapy
timeFrame: 2 years
measure: Response rate following neo-adjuvant chemotherapy
timeFrame: 2 years
measure: Rate of fertility sparing surgery
timeFrame: 2 years
measure: Surgical complication rate following fertility sparing surgery
timeFrame: 2 years
measure: Rate of recurrence-free survival
timeFrame: 2 years
measure: Rate of recurrence-free survival
timeFrame: 3 years
measure: Overall survival for patients who undergo neo-adjuvant chemotherapy followed by fertility sparing surgery
timeFrame: 2 years
measure: Overall survival for patients who undergo neo-adjuvant chemotherapy followed by fertility sparing surgery
timeFrame: 3 years
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson Cancer Centre
state: Texas
city: Toronto
country: Canada
facility: Sunnybrook Health Sciences Centre
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
city: Québec
country: Canada
facility: L'Hôtel-Dieu de Québec
state: Quebec
Study officials:
affiliation: Princess Margaret Cancer Centre
name: Stephanie Lheureux, M.D.
role: PRINCIPAL_INVESTIGATOR
References: